Huadong Medicine Co. Ltd. recently detailed the discovery and preclinical characterization of a potent and selective small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist, HDM-1002, under investigation for the treatment of type 2 diabetes and obesity.